Juno Therapeutics to Present at November 2017 Investor Conferences
November 06 2017 - 3:05PM
Business Wire
Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it
will webcast its presentations at two investor conferences in
November. The presentations will feature a business overview and
update by Steve Harr, Juno’s Chief Financial Officer and Head of
Corporate Development.
- Juno will present at the 26th Annual
Credit Suisse Healthcare Conference at 9:15 a.m. Mountain Time (MT)
on Wednesday, November 8, 2017.
- Juno will present at the Evercore ISI
Biopharma Catalyst / Deep Dive Conference at 8:45 a.m. Eastern Time
(ET) on Wednesday, November 29, 2017.
The webcasts will be accessible on the Investor Relations page
of Juno's website at www.JunoTherapeutics.com. A replay of each
presentation will be available at the same location for 30 days
following the corresponding conference.
About Juno
Juno Therapeutics is building a fully integrated
biopharmaceutical company focused on developing innovative cellular
immunotherapies for the treatment of cancer. Founded on the vision
that the use of human cells as therapeutic entities will drive one
of the next important phases in medicine, Juno is developing
cell-based cancer immunotherapies based on chimeric antigen
receptor and high-affinity T cell receptor technologies to
genetically engineer T cells to recognize and kill cancer. Juno is
developing multiple cell-based product candidates to treat a
variety of B-cell malignancies as well as multiple solid tumors and
multiple myeloma. Several product candidates have shown compelling
clinical responses in clinical trials in refractory leukemia and
lymphoma conducted to date. Juno's long-term aim is to leverage its
cell-based platform to develop new product candidates that address
a broader range of cancers and human diseases. Juno brings together
innovative technologies from some of the world's leading research
institutions, including the Fred Hutchinson Cancer Research
Center, Memorial Sloan Kettering Cancer Center, Seattle
Children's Research Institute (SCRI), the University
of California, San Francisco, and The National
Cancer Institute. Juno Therapeutics has an exclusive
license to the St. Jude Children’s Research Hospital patented
technology for CD19-directed product candidates that use 4-1BB,
which was developed by Dario Campana, Chihaya Imai, and
St. Jude Children’s Research Hospital. Juno’s product
candidate JCAR017 was developed in collaboration with SCRI and
others.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933, and Section 21E of
the Securities Exchange Act of 1934, including statements regarding
Juno’s mission, progress, and business plans, Juno’s participation
at the 26th Annual Credit Suisse Healthcare Conference and the
Evercore ISI Biopharma Catalyst / Deep Dive Conference, and the
subject matter of Juno's presentations at the conferences.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from such
forward-looking statements, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to, risks associated
with: the success, cost, and timing of Juno's product development
activities and clinical trials; Juno's ability to obtain regulatory
approval for and to commercialize its product candidates; with
respect to the timing of JCAR017 approval, the time it takes to
complete enrollment of the pivotal cohort, the timing of Juno’s FDA
submission, and the duration of FDA review; Juno's ability to
establish a commercially-viable manufacturing process and
manufacturing infrastructure; regulatory requirements and
regulatory developments; success of Juno's competitors with respect
to competing treatments and technologies; Juno's dependence on
third-party collaborators and other contractors in Juno's research
and development activities, including for the conduct of clinical
trials and the manufacture of Juno's product candidates; Juno’s
ability to attract and retain key scientific, quality
control/assurance, manufacturing or management personnel; Juno's
dependence on Celgene for the development and
commercialization outside of North
America and China of Juno’s CD19 product candidates
and any other product candidates for
which Celgene exercises an option; Juno’s dependence
on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does
not exercise complete control, for the development and
commercialization of product candidates in China; Juno's
ability to obtain, maintain, or protect intellectual property
rights related to its product candidates; amongst others. For a
further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Juno's
business in general, see Juno's Quarterly Report on Form 10-Q filed
with the Securities and Exchange
Commission on November 1, 2017 and Juno’s other
periodic reports filed with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. Juno disclaims any obligation to update these
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171106006264/en/
Juno TherapeuticsInvestor Relations:Nicole Keith,
206-566-5521nikki.keith@junotherapeutics.comorMedia:Christopher
Williams, 206-566-5660chris.williams@junotherapeutics.com
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Apr 2024 to May 2024
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From May 2023 to May 2024